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Safetya b s t r a c t
This study assessed the safety and persistence of dengue neutralising antibodies for ﬁve years after
administration of a recombinant live, attenuated, tetravalent dengue vaccine (TDV). Participants aged
2–45 years (n = 126) were randomised at a single centre in the Philippines to receive TDV vaccinations
at months 0, 3–4, and 12 (TDV–TDV–TDV group) or licensed typhoid vaccination (TyVi) at month 0
and TDV at months 3–4 and 12 (TyVi–TDV–TDV group). Dengue antibodies were measured annually (pla-
que reduction neutralisation test). Participants with suspected dengue underwent laboratory testing. No
safety concerns were reported throughout the study. Six dengue cases were virologically conﬁrmed, but
assessed as non-severe dengue disease. Geometric mean titres throughout the follow-up period remained
2- to 4-fold higher than at baseline for all serotypes, ages and study groups. Approximately 10% of par-
ticipants annually were exposed to wild-type dengue, which contributed to persistently higher titres
compared with non-infected participants. In conclusion, TDV appears to have good safety and persistence
of antibodies over ﬁve years.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Dengue is an important vector-borne infectious disease glob-
ally, and represents a signiﬁcant health burden in tropical and sub-
tropical regions of the world where it is endemic [1]. An estimated
50–100 million dengue infections occur annually worldwide,
resulting in over 2 million cases of dengue disease. There are cur-
rently no speciﬁc antiviral treatments for dengue, and infection
control measures are mainly limited to environmental risk reduc-
tion such as elimination of mosquito populations. A recombinant
yellow fever-17D–dengue virus, live, attenuated, tetravalent den-
gue vaccine (TDV) is currently in development and has already
undergone extensive clinical trials to date [2–10].
A Phase I study was conducted in the Philippines, a country
endemic for dengue, to assess the safety and immunogenicity of
TDV over a ﬁve-year follow-up period. The aim of this study was
to describe safety and persistence of antibodies up to ﬁve years fol-
lowing administration of TDV, as well as the number of denguecases through passive surveillance of febrile episodes and the inci-
dence of dengue infection. Safety and immunogenicity data during
the 12 month vaccination schedule and up to 28 days after the last
vaccination has previously been reported [11]. Here we report fol-
low-up to ﬁve years after the last vaccination.Methods
The study design, inclusion and exclusion criteria, and vaccina-
tion schedule have been described in detail elsewhere [11]. In brief,
126 participants aged 2–45 years were randomised at a single
study centre in the Philippines to receive three TDV injections at
0, 3–4 and 12 months (TDV–TDV–TDV group; n = 84) or one injec-
tion with a licensed control typhoid vaccine (TyphimVi) at month
0, followed by two TDV injections at 3–4 and 12 months (TyVi–
TDV–TDV group; n = 42). Participants were followed-up for ﬁve
years after the last study injection. Serious adverse events (SAEs)
were recorded throughout the study. Pregnancy outcomes were
reported for the ﬁrst two years of follow-up. Diagnostic tests for
laboratory-conﬁrmation of dengue infection (dengue NS1 antigen
Enzyme-Linked Immunosorbent Assay [ELISA](Platelia™, Bio-Rad
Laboratories), serotype-speciﬁc dengue reverse transcriptase
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were performed in participants with suspected dengue i.e., partici-
pants with febrile episodes (temperature P38 C for P48 h) dur-
ing the ﬁrst four years of follow-up and hospitalised cases only
during the ﬁfth year. Serological conﬁrmation of dengue infection
was deﬁned as presence of dengue IgM and/or IgG, and virologi-
cally conﬁrmed by detection of dengue NS1 antigen and/or ampli-
ﬁed genomic sequences. Serum samples for immunogenicity
analyses were taken at baseline, 28-days after each study injection
and annually after the last injection. Serum neutralising antibody
levels to each of the four parental wild-type dengue virus strains
were determined using a 50% plaque reduction neutralisation test
(PRNT50) [12]. Exposure to wild-type dengue was deﬁned as a
4-fold increase in PRNT50 antibody titre (and with a resultant titre
P40) for at least one serotype between two consecutive years
(with no missing data for any serotype at both time points). No
hypothesis testing was carried out in this study; descriptive statis-
tics were used to summarise the data. Geometric mean titres
(GMTs) were determined with and without exclusion of partici-
pants who had been exposed to wild-type dengue.
It should be noted that an optimised PRNT assay was developed
and validated for assessment of vaccine immunogenicity during
the follow-up period. Baseline, post-vaccination and follow-up
samples from the study were then tested with this single assay
to generate a complete dataset, [12] as such the GMTs reported
here for baseline and after the third vaccination differ from those
reported previously [11].Results
A total of 126 participants received study vaccination at month
0 of the study, of whom 113 completed the ﬁve year follow-up. The
baseline characteristics of the participants are summarised else-
where [11].
There were no vaccine-related SAEs reported during the ﬁve
year follow-up period in either study group. Only two SAEs were
reported; both occurred during the ﬁfth year of follow up in the
TDV–TDV–TDV group. The ﬁrst was a hospitalisation for myofascial
pain syndrome in a 19 year old female participant, and the second
a dengue episode in a 10 year old boy who was hospitalised with
fever, abdominal pain, and vomiting. The hospitalised boy had
virologically-conﬁrmed dengue (serotype 1), but did not haveTable 1
Laboratory-conﬁrmed dengue cases during the ﬁve-year follow-up period.
Time of
occurrence*
Group Age Pre-infection PRNT50 antibody
titres to infecting serotype
1st year follow-up TDV–TDV–TDV 6–11 years DEN-1: 41; DEN-2: 96;
DEN-3:143; DEN-4: 19
2nd year follow-up TDV–TDV–TDV 2–5 years DEN-1: < 10; DEN-2: 43;
DEN-3:<10; DEN-4: 87
3rd year follow-up TyVi–TDV–TDV 2–5 years DEN-1: 53; DEN-2: 215;
DEN-3: 5659; DEN-4: 303
4th year follow-up TDV–TDV–TDV 2–5 years DEN-1:<10; DEN-2: 36;
DEN-3: 37; DEN-4: 36
4th year follow-up TyVi–TDV–TDV 6–11 years DEN-1:<10; DEN-2:<10;
DEN-3:<10; DEN-4:<10
4th year follow-up TyVi–TDV–TDV 12–17 years DEN-1: 88; DEN-2: 86;
DEN-3: 2057; DEN-4: 86
5th year follow-up TDV–TDV–TDV 2–5 years DEN-1:<10; DEN-2:<10;
DEN-3: 51; DEN-4: 31
IgG, Gamma immunoglobulin; IgM, M immunoglobulin; N/A, not available; PRNT50, 50%
reaction.
* During the ﬁrst four years of follow-up, laboratory tests to conﬁrm dengue infection
(temperature P38 C for P48 ). In the 5th year of the follow-up, these tests were perfosevere dengue according to the World Health Organization 2009
classiﬁcation (i.e. no sign of shock, haemorrhage, plasma leakage,
or thrombocytopenia) and recovered four days after fever onset
and discharged two days later (6 days after fever onset). Four
women became pregnant during follow up; none of these pregnan-
cies were exposed to vaccination. There were no complications
with the pregnancies and the women delivered healthy babies.
During the ﬁrst four years of follow up, 53 febrile episodes (sus-
pected dengue disease) were reported by 34 participants (20 in the
TDV–TDV–TDV group and 14 in the TyVi–TDV–TDV group), most of
whom (n = 28) were children aged 2–11 years. Among the sus-
pected dengue disease cases in the ﬁrst four years (three in the
TDV–TDV–TDV group and three in the TyVi–TDV–TDV group), six
were laboratory conﬁrmed and of these, ﬁve were virologically
conﬁrmed (Table 1). In the case where dengue was laboratory con-
ﬁrmed but not virologically conﬁrmed, the subject was positive for
anti-dengue IgG and IgM but negative for RT-PCR and NS1 Ag.
During the ﬁfth year of follow-up, one additional dengue case
(virologically conﬁrmed) was reported in a boy in the 2–5 year
old group (Table 1). Overall, of the seven dengue cases that
occurred during this study, four subjects were dengue seropositive
and three subjects were seronegative at baseline (prior to
vaccination).
Fig. 1 summarises the serotype speciﬁc seropositivity rates
(titres >10) during follow up across the two study groups. The
GMTs for the four dengue serotypes decreased during follow up.
The decrease was most pronounced within the ﬁrst year post-
vaccination, but remained 2- to 4-fold higher than at baseline over
the ﬁve years of follow-up for all serotypes, age groups and study
groups. There was little difference in GMTs for each serotype
between the two groups for the duration of follow up
(Supplementary Fig. 1). Natural exposure to wild-type dengue, as
determined by a 4-fold increase in PRNT50 titre (and with a resul-
tant titreP40), occurred in approximately 10% of participants each
year (35 out of 77 participants in the TDV–TDV–TDV group had
evidence of at least one episode of exposure to wild-type dengue).
Participants with no evidence of natural exposure to wild-type
dengue in the TDV–TDV–TDV group had generally lower seroposi-
tivity rates (data not shown), particularly over time, and lower
GMT levels for all dengue serotypes compared with all participants
throughout follow up (Fig. 2), suggesting that natural exposure to
wild-type dengue boosted immunogenicity of all serotypes. The




Positive Positive Positive Negative Yes No
Positive Positive Positive Negative Yes No
Positive Positive Negative Negative No No
Positive Positive Positive Serotype 1 Yes No
Positive Positive Positive Serotype 2 Yes No
Negative Negative Positive Serotype 1 Yes No
Positive Positive Positive Serotype 1 Yes Yes
plaque reduction neutralising test; RT-PCR, reverse transcriptase polymerase chain
were performed in all participants with suspected dengue i.e. with febrile episodes
rmed in hospitalised cases only.
Fig. 1. Serotype-speciﬁc seropositivity rates (PRNT50 P10) up to 5 years post-ﬁnal vaccination for the TDV–TDV–TDV and TyVi–TDV–TDV groups (pre-dose and post-ﬁnal
refer to baseline and 28 days after the third vaccination, respectively).
Fig. 2. Geometric mean titres (GMTs) and 95% CIs for each dengue serotype in the TDV–TDV–TDV group over time in all participants and in participants without natural
exposure to wild-type dengue (pre-dose and post-ﬁnal refer to baseline and 28 days after the third vaccination, respectively).
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Fig. 3. Geometric mean titres (GMTs) and 95% CIs for each dengue serotype in the TDV–TDV–TDV and TyVi–TDV–TDV groups over time by baseline ﬂavivirus serostatus (pre-
dose and post-ﬁnal refer to baseline and 28 days after the third vaccination, respectively).
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TDV–TDV group (data not shown). Higher GMTs were observed
for all time points in participants who were ﬂavivirus positive at
baseline (Fig. 3).Discussion
This is the ﬁrst study to demonstrate the safety and persistence
of antibodies for ﬁve years in TDV recipients exposed to wild-type
dengue virus. The excellent retention of the study participants (113
out of 126) and compliance with the protocol contributes to the
reliability of the results. There were no safety concerns over the
5-year follow up, conﬁrming the good safety proﬁle of TDV in this
setting. Study participants who became infected with dengue did
not develop severe disease. In those with virologically-conﬁrmed
dengue, most had neutralising titres below the lower limit of
quantitation (<10) at the assessment time point before infection
to the infecting serotype. Exposure to circulating wild-type dengue
virus boosted antibody levels not only to the relevant serotype but
also to the other serotypes (>10-fold increase). Five years after the
last TDV injection, neutralising antibody levels to all four serotypes
were similar to those at the end of the ﬁrst year of follow-up and
comparable between study groups. Following an initial decline in
GMTs after the last injection to the end of the ﬁrst year of fol-
low-up, GMTs were relatively stable during the follow-up period,
with annual ﬂuctuations due to natural exposure to wild-type den-
gue. Exposure to wild-type dengue contributed to antibody persis-
tence in this setting.
Our study has a few limitations. No control group was included
in the study and therefore it was not possible to determine if the
candidate vaccine provided any added beneﬁt over what would
be expected following exposure to subclinical and symptomatic
natural dengue infections. The TyVi–TDV–TDV group received onlytwo TDV doses which is inconsistent with the three-dose schedule
used more recently in the development program for this vaccine
candidate. Nonetheless, the immunogenicity achieved with the
two TDV doses appears similar to that achieved with three doses
over the duration of follow up. However, it is not possible from this
study to conclude whether a two- or three-dose TDV schedule
should be recommended with this vaccine candidate. Although
participants in the TDV–TDV–TDV group received three TDV doses,
the schedule used also differs from the schedule (0, 6 and
12 months) being assessed in current Phase II/III clinical trials.
Furthermore, no control group was included in this study (all par-
ticipants were vaccinated) to determine the comparative rate for
background exposure to wild-type dengue in a non-vaccinated
population living in this area (in the absence of solid epidemiologi-
cal data). The sample size was relatively small and only seven den-
gue cases were laboratory conﬁrmed during the follow-up period.
Although four of these cases occurred during the last two years of
follow up, when dengue antibodies might have diminished, no
solid conclusion can be drawn from the low number of cases,
and a correlation between antibody level and protection from the
disease has not been determined.
Overall, the rate of annual exposure to wild-type dengue
(approximately 10%) and the exposure to dengue:dengue disease
ratio in the current study were higher than in other cohort studies
conducted in endemic areas in Asia or Latin America [13–15].
However, the proportion of symptomatic cases to overall exposure
to dengue were shown to vary substantially between years in a
seven-year longitudinal study [15]. It is possible that we may have
overestimated the rate of exposure to wild-type dengue in our
study, which was deﬁned as a 4-fold increase in dengue antibodies.
This threshold may not be not stringent enough even for annual
samples, considering the greater than 10-fold rise in antibodies
observed in acute and convalescent samples from laboratory-
conﬁrmed dengue cases. In addition, the comparability of estimated
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be hampered by the lack of a standardised/harmonised PRNT assay,
[16] which may result in wide variations in PRNT titres between
studies as a result of slightly varied assay conditions. It is also pos-
sible that we may have underestimated the number of dengue
cases as the passive reporting of febrile episodes might have led
to clinically mild or asymptomatic cases being missed.
Vaccination of participants in this trial might have generated pro-
tection against clinical dengue, without a sterilising immunity,
leading to this high ratio compared to previously published data.
Alternatively, differences in serotype and virulence of circulating
dengue viruses, population age and baseline ﬂavivirus/dengue sta-
tus between this study and previous studies or a combination of
several factors may offer some explanation for the observed differ-
ences in the exposure to dengue:dengue disease ratios.
In conclusion, TDV appears to have good safety and persistence
of antibodies over the 5-year follow up period, however, larger
phase II/III trials are warranted to conﬁrm these results.
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